Drug Trial Radar · NCT00783432
Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Oct 6, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
862
Actual
Start
Jul 2006
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- Meda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
Conditions
- Chronic Allergic Rhinitis
- Nonallergic Rhinitis
Interventions
Astepro Nasal Spray (0.1% azelastine hydrochloride)Drug
548 mcg (2 sprays per nostril) twice a day
Astelin Nasal Spray (0.1% azelastine hydrochloride)Drug
548 mcg (2 sprays per nostril) twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Adverse EventsTime frame: 12 months
- Focused Examination of the Head and Neck With Findings Recorded on a Numeric Scale.Time frame: baseline and 12 months/ET
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Meda Clinical Trials Contact Center
Somerset, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.